Email Alert | RSS    帮助

中国防痨杂志 ›› 2022, Vol. 44 ›› Issue (11): 1107-1121.doi: 10.19982/j.issn.1000-6621.20220239

• 专题笔谈 • 上一篇    下一篇

免疫活性物质:结核病和非结核分枝杆菌病治疗的新选择

龚文平, 米洁, 吴雪琼()   

  1. 中国人民解放军总医院第八医学中心结核病医学部研究所/结核病防治重点实验室/结核病诊疗新技术北京市重点实验室,北京 100091
  • 收稿日期:2022-06-22 出版日期:2022-11-10 发布日期:2022-11-03
  • 通信作者: 吴雪琼 E-mail:xueqiongwu@139.com
  • 基金资助:
    国家自然科学基金(81801643);北京市自然科学基金(19L2065);北京市科委首都特色临床课题(Z181100001718005);中国人民解放军总医院青年基金(QNC19047)

Immunologically active substances: novel treatment options for tuberculosis and nontuberculous mycobacteriosis

Gong Wenping, Mi Jie, Wu Xueqiong()   

  1. Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment/Senior Department of Tuberculosis, the 8th Medical Center of PLA General Hospital, Beijing 100091, China
  • Received:2022-06-22 Online:2022-11-10 Published:2022-11-03
  • Contact: Wu Xueqiong E-mail:xueqiongwu@139.com
  • Supported by:
    National Natural Science Foundation of China(81801643);Beijing Municipal Science & Technology Commission(19L2065);Beijing Municipal Science & Technology Commission(Z181100001718005);Chinese PLA General Hospital(QNC19047)

摘要:

结核病不仅是一种传染性疾病,也是一种免疫性疾病。免疫疗法是一种潜在的结核病和非结核分枝杆菌病治疗手段,可以通过影响和调节人体的免疫系统来抑制甚至清除结核分枝杆菌和非结核分枝杆菌。本文中,笔者就治疗结核病和非结核分枝杆菌病的免疫活性物质如细胞因子、抗体、小分子活性肽、溶菌酶及免疫阻滞剂等的研究进展进行总结和凝练,以期为结核病和非结核分枝杆菌病的治疗提供新思路。

关键词: 结核, 分枝杆菌感染, 免疫疗法, 主动, 佐剂, 免疫, 总结性报告(主题)

Abstract:

Tuberculosis (TB) is not only an infectious disease, but also an immune disease. As a new potential treatment for diseases caused by the Mycobacterium tuberculosis (MTB) and nontuberculous mycobacteria (NTM), immunotherapy can inhibit or even eliminate MTB and NTM by influencing and regulating the immune system of the human body. In this article, we summarized the research progress of immunologically active substances such as cytokines, antibodies, small molecule active peptides, lysozyme, and immunoblockers in the treatment of MTB and NTM infections. This study will provide new ideas for TB and NTM treatment.

Key words: Tuberculosis, Mycobacterium infections, Immunotherapy, active, Adjuvants, immunologic, Consensus development conferences as topic

中图分类号: